Literature DB >> 20716246

The failure to show bioequivalence is not evidence against generics.

Alfredo García-Arieta.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20716246      PMCID： PMC2949920          DOI： 10.1111/j.1365-2125.2010.03684.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  1 in total

1.  Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.

Authors:  Mario Del Tacca; Giuseppe Pasqualetti; Antonello Di Paolo; Agostino Virdis; Gabriele Massimetti; Giovanni Gori; Daniele Versari; Stefano Taddei; Corrado Blandizzi
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335
  1 in total
  3 in total

1.  Pilot and Repeat Trials as Development Tools Associated with Demonstration of Bioequivalence.

Authors:  Anders Fuglsang
Journal:  AAPS J       Date:  2015-03-04       Impact factor: 4.009

2.  Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.

Authors:  Vangelis Karalis; Panos Macheras; Meir Bialer
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

3.  Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products.

Authors:  Gopal Pawar; Fang Wu; Liang Zhao; Lanyan Fang; Gilbert J Burckart; Kairui Feng; Youssef M Mousa; Franci Naumann; Hannah K Batchelor
Journal:  AAPS J       Date:  2021-04-21       Impact factor: 4.009
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.